Volume 23, Number 6—June 2017
Research
Distribution and Quantitative Estimates of Variant Creutzfeldt-Jakob Disease Prions in Tissues of Clinical and Asymptomatic Patients
Table 1
Dilution | Transmission in tgBov mice |
|
---|---|---|
No. positive mice/no. tested | Mean ± SD, incubation, d | |
Undiluted | 6/6 | 249 ± 2 |
10−1 | 6/6 | 283 ± 15 |
10−2 | 6/6 | 316 ± 21 |
10−3 | 6/6 | 342 ± 10 |
10−4 | 6/6 | 453 ± 66 |
10−5 | 2/6 | 479, 495† |
10−6 | 1/6 | 502† |
10−7 | 0/6 | >700 |
*A 10% (wt/vol) homogenate was prepared by using frontal cortex from a clinically affected patient with vCJD. Groups of 6 tgBov mice were inoculated intracerebrally with 20 μL of serial 10-fold dilutions of this homogenate. Mice were considered positive when abnormal prion protein deposition was detected in the brain. vCJD, variant Creutzfeldt-Jakob disease.
†Dilutions at which <50% of mice were positive.
Page created: May 16, 2017
Page updated: May 16, 2017
Page reviewed: May 16, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.